Navigation Links
Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
Date:9/16/2011

MOUNTAIN VIEW, Calif., Sept. 16, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal.  The presentations highlighted the long-term beneficial effects of QNEXA treatment in metabolically-impaired patients with prediabetes, diabetes, and metabolic syndrome.

The QNEXA presentations included:  

  • Decreased Progression to Diabetes in Subjects With Prediabetes After 2 Years of Treatment With Controlled-Release Phentermine/Topiramate, authored by W. Timothy Garvey, MD, et al.
  • Long-Term Weight Loss With Controlled-Release Phentermine/Topiramate Reverses Metabolic Syndrome and Improves Associated Traits, authored by Hermann Toplak, MD, et al.
  • Long-Term Glycaemic Effects of Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate in Overweight/Obese Subjects with Diabetes, authored by Luc F. Van Gaal, MD, et al.

    • Highlights from the EASD presentations are as follows:

    A poster presentation authored by W. Timothy Garvey, MD from the University of Alabama at Birmingham reported that patients treated over two years with QNEXA had significant reductions in the progression to type 2 diabetes and improvement in glycemic status. Of the 675 patients in the two-year SEQUEL study, 316 were determined to have prediabetes at baseline. In the prediabetic sub-group treated with QNEXA, all glycemic parameters were significantly improved at week 108 (ITT-LOCF; P<0.05 vs. placebo). Progression to diabetes was reduced in the prediabetic sub-group with top-dose QNEXA vs. placebo (P=0.0125).  

    Luc Van Gaal, MD from the University of Antwerp in Belgium and Lawrence Cheskin, MD from Johns Hopkins University Weight Management Center authored a poste
    '/>"/>

    SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5

    Related medicine technology :

    1. VIVUS Provides Regulatory Update on QNEXA
    2. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
    3. Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
    4. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
    5. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
    6. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
    7. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
    8. VIVUS Provides Regulatory Update on QNEXA NDA
    9. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
    10. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
    11. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... BOSTON , May 17, 2013  TechAtlas ... update for their competitive landscape map for the ... highlights over 90 international companies with drugs and ... addressing CKD and its sequelae. ... include: , hypertension - renal denervation ...
    (Date:5/17/2013)... Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) ... new, patent-pending technologies poised to redefine how consumers receive energy, ... a business update teleconference and webcast for shareholders and the ... 4:30 PM ET. Fuse Science, Inc. CEO, ... and will be joined by Rubin Hanan ...
    (Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
    Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
    (Date:5/19/2013)... People in Minnesota have a great option to get in ... Day Fat Loss Formula. The best part is people ... home. The product sells for $135 dollars and is an ... http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is almost here. People ... using the 28 Day Fat Loss Formula they will be ...
    (Date:5/19/2013)... City, Utah (PRWEB) May 19, 2013 ... information on small business health insurance . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... start-ups, and the self-employed intrinsically know the value ...
    (Date:5/19/2013)... May 19, 2013 These molecular ... US, UK, Spain, Japan, Italy, Germany and France:, ... molecular diagnostics laboratory practice, as well as key ... significant market impact during the next five years. ... and biochip technologies, test formats, detection methodologies, trends ...
    (Date:5/19/2013)... (PRWEB) May 19, 2013 Americans live ... to the newest American Veterinary Medical Association (AVMA) U.S. ... American dog owners consider their dog a member of ... had said as much five years earlier. , According ... value of the national income dedicated to pets has ...
    (Date:5/19/2013)... Las Vegas, Nevada (PRWEB) May 19, 2013 ... travel agency , is proud to announce the launch ... Music Awards at the MGM Grand on 5/19/2013. Consumers ... the all new special pricing available on VegasHotelEscapes.com's website. ... guarantee that they beat any competitors price. , Vegas ...
    Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3
    ... Feb. 10 During scheduled visits to Members of ... Homecare and its members will urge Congress and the ... the Medicare Anti-Fraud Legislative Plan. Developed by the ... tough, effective measures to stop waste, fraud and abuse ...
    ... researchers say , , TUESDAY, Feb. 10 (HealthDay News) -- ... even bother to use them because they,re difficult to ... are allowing the brain to communicate directly with artificial ... banana and fold laundry. , "In the simplest terms, ...
    ... even if you stop taking the drug, study finds , , ... aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to reduce ... cancer. , That,s the conclusion of a new study of ... clear, and arguably proven, that NSAID drugs do interfere with ...
    ... of Potential Surrogate Endpoints of Long-Term Survival in Prostate ... distant metastases 3 years after the start of treatment ... with early prostate cancer. , Prostate cancer is a ... history of the disease makes evaluation of new therapies ...
    ... percent as a result of My Health programLOS ... Institute (IBI) and the National Business Coalition on ... the 2009 IBI/NBCH Healthy Workforce Productivity Award at ... 9-11 in Los Angeles. The award, sponsored by ...
    ... to have an effect on whether a patient with terminal ... by researchers at Beth Israel Deaconess Medical Center (BIDMC). Published ... the American Geriatrics Society ( JAGS ), the findings ... services less frequently than do whites and Hispanics. , According ...
    Cached Medicine News:Health News:American Association for Homecare Proposes to Congress a Medicare Anti-Fraud Action Plan that Includes Increased Penalties, Site Inspection, and Tough Standards 2Health News:American Association for Homecare Proposes to Congress a Medicare Anti-Fraud Action Plan that Includes Increased Penalties, Site Inspection, and Tough Standards 3Health News:American Association for Homecare Proposes to Congress a Medicare Anti-Fraud Action Plan that Includes Increased Penalties, Site Inspection, and Tough Standards 4Health News:New Technology May Boost Artificial Arms 2Health News:Long-Term Aspirin Use Seems to Protect Against Colorectal Lesions 2Health News:Long-Term Aspirin Use Seems to Protect Against Colorectal Lesions 3Health News:Also in the Feb. 10 JNCI 2Health News:Also in the Feb. 10 JNCI 3Health News:Also in the Feb. 10 JNCI 4Health News:Also in the Feb. 10 JNCI 5Health News:Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award 2Health News:Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award 3Health News:Study finds race and ethnicity affect use of hospice services among patients with advanced cancer 2
    6 mm x 23 mm blunt, double-edged blade. Flat handle....
    7 mm blade, angled right. Flat handle....
    5 mm x 8 mm "D" shaped knife. Flat handle. Designated most popular model or size....
    1 mm diameter. Angled 33 degrees. Round handle....
    Medicine Products: